Analysed CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) News Sources
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
29-04-2026
yahoo.com
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
13-05-2026
yahoo.com
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
14-05-2026
yahoo.com
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
26-05-2026
yahoo.com
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9
05-06-2026
yahoo.com
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
23-06-2026
yahoo.com
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
24-06-2026
yahoo.com
What is the current price of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)?
The current price of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) is $0.0055.
CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) absolute price change since previous trading day?
The absolute price change of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) since the previous trading day is $0.0005.
CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) percentage price change since previous trading day?
The percentage price change of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) since the previous trading day is 10%.
What is the most recent average sentiment score for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)?
The most recent average sentiment score for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) is 78 out of 100.
What is the most recent average sentiment for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)?
The most recent sentiment for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) is .
SEC-8K** Filing Available For CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.